Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors

Ginkgo Bioworks Holdings ( (DNA) ) has provided an update.

On June 12, 2025, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, where a significant majority of shares were represented. The meeting resulted in the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, shareholders approved the executive compensation on an advisory basis, indicating broad support for the company’s leadership and strategic direction.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Spark’s Take on DNA Stock

According to Spark, TipRanks’ AI Analyst, DNA is a Neutral.

Ginkgo Bioworks Holdings is navigating significant financial difficulties with consistent net losses and negative cash flows, impacting its stock valuation. Technical indicators show mixed short-term trends, and while there is strategic progress in cost reductions and business expansion, the macroeconomic challenges continue to pose risks. The cautiously optimistic outlook from the latest earnings call slightly offsets these challenges, but the overall risk remains high.

To see Spark’s full report on DNA stock, click here.

More about Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. operates in the biotechnology industry, focusing on the development of synthetic biology solutions. The company is known for its work in designing custom organisms for a variety of industries, including pharmaceuticals, agriculture, and industrial chemicals.

Average Trading Volume: 1,242,590

Technical Sentiment Signal: Hold

Current Market Cap: $572.4M

Find detailed analytics on DNA stock on TipRanks’ Stock Analysis page.